Trials / Terminated
TerminatedNCT00225056
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (planned)
- Sponsor
- Oncology Specialties, Alabama · Academic / Other
- Sex
- Female
- Age
- 19 Years – 85 Years
- Healthy volunteers
- —
Summary
In this phase II study, we plan to evaluate the efficacy, safety and tolerability of weekly docetaxel and capecitabine on a 21-day cycle followed by maintenance single agent capecitabine for the treatment of metastatic breast cancer, Based on the efficacy and toxicity of the combination regimen dosages previously reviewed; weekly docetaxel 30mg/m2 on days 1 and 8 plus capecitabine 1600mg/m2 (800mg/m2 orally twice daily)on day 1 through 14 of each cycle will be utilized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | docetaxel and capecitabine |
Timeline
- Start date
- 2003-10-01
- Completion
- 2006-11-01
- First posted
- 2005-09-23
- Last updated
- 2007-04-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00225056. Inclusion in this directory is not an endorsement.